Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug resistance.

R L Fine

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1988
    PubMed
    Summary
    This summary is machine-generated.

    Recent advances in understanding multidrug resistance (MDR) mechanisms offer new therapeutic strategies. However, the clinical relevance of in-vitro MDR and co-existing resistance in tumors remains uncertain.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Medical futility and the Texas Advance Directives Act of 1999.

    Proceedings (Baylor University. Medical Center)·2006
    Same author

    Depression, anxiety, and delirium in the terminally ill patient.

    Proceedings (Baylor University. Medical Center)·2005
    Same author

    Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells.

    Proceedings of the National Academy of Sciences of the United States of America·2001
    Same author

    Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.

    Oncology·2001
    Same author

    The Texas Advance Directives Act of 1999: politics and reality.

    HEC forum : an interdisciplinary journal on hospitals' ethical and legal issues·2001
    Same author

    The rise and fall of the futility movement.

    The New England journal of medicine·2001
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Molecular Biology

    Background:

    • Multidrug resistance (MDR) is a significant challenge in cancer therapy.
    • Recent scientific advancements have rapidly improved the understanding of MDR mechanisms.

    Purpose of the Study:

    • To review the recent progress in understanding multidrug resistance.
    • To discuss the potential clinical applications of new findings in MDR therapies.

    Main Methods:

    • Literature review of recent studies on multidrug resistance mechanisms.
    • Analysis of new inhibitors, screening techniques, and therapeutic strategies for MDR.
    • Discussion of the translation of in-vitro findings to clinical practice.

    Main Results:

    Related Experiment Videos

    • Significant progress has been made in elucidating MDR mechanisms.
    • New MDR inhibitors and equitoxic agents are emerging.
    • Advanced screening techniques and therapeutic applications are being developed.

    Conclusions:

    • Clinical oncologists may soon have access to novel MDR-targeting agents and therapies.
    • A critical question remains whether in-vitro MDR accurately reflects clinical resistance.
    • Other resistance mechanisms may coexist with MDR in patient tumors, complicating treatment.